



Wilson Aarhus

2026

Final Program

Thursday April 30

19.00-21.30 Welcome dinner at the venue Comwell, Værkmestergade 2, DK-8000 Aarhus C

Friday May 1

Morning

9.00 Welcome *President, Thomas Sandahl (Aarhus)*

Session I: Welcome session

Chairs: Thomas Sandahl, Svetlana Lutsenko

9.10 WDGA – Wilson Disease Global Alliance *Lisbet Ottesen (Copenhagen)*

9.30 Gut-liver-brain Interactions *Valentina Medici (Sacramento)*

9.50 The Brain and Copper: Beyond Wilson Disease *Aurélia Poujois (Paris)*

10.10 Incorporating meaningful endpoints for treatment of WD into practice - role of NIT *Michael Schilsky (New Haven)*

10.30 Coffee break

Session II: Neurology I

Chairs: Aurélia Poujois, Petr Dusek

11.00 Modified UWDRS *Petr Dusek (Prague)*

11.20 The added value of Neurophysiology in WD with movement disorder *Mickael Alexandre Obadia (Paris)*

11.35 Is r-TMS the future treatment for dysarthria in WD *Michaela Pernon (Paris)*

11.50 Abs 37: Visualizing retention of brain copper in a rat model of Wilson disease: a ⁶⁴Cu PET study *Nicole Antolini (Aarhus)*

12.05 Abs 54: Longitudinal trajectory of psychiatric syndromes in Wilson disease *Paula Zimbrea (New Haven)*

12.20 Abs 49: Validation of the Düsseldorf Scale for WD *Lira Janbolot (Düsseldorf)*

12.35 Lunch

Friday May 1

Afternoon

Session III: Epidemiology*Chairs: Tomasz Litwin, Karl Heinz Weiss*

- | | | |
|-------|---|--|
| 13.30 | Wilson Disease in China: Clinical and Genetic Insights from a Large Cohort | <i>Zhi-Ying Wu (Hangzhou)</i> |
| 13.50 | Has presenting phenotype and its relation to gender changed over the years? | <i>Karina Rewitz (Aarhus)</i> |
| 14.05 | Wilson disease in Brazil | <i>Marta Mitiko Deguti (Sao Paulo)</i> |
| 14.20 | Abs 56: Elastopathy in Wilson disease: a cohort study of 172 patients | <i>Dominique Debray (Paris)</i> |

Session IV: Poster session

- | | | |
|-------|---------------------------------|--|
| 14.35 | Poster viewing and coffee break | |
|-------|---------------------------------|--|

Session V: ALF in WD*Chairs: Seema Alam, Marina Berenguer, Tudor Pop*

- | | | |
|-------|---|----------------------------------|
| 16.00 | ALF in Wilson disease | <i>Anil Dhawan (London)</i> |
| 16.20 | NCC in the diagnosis of ALF | <i>Eduardo Couchonnal (Lyon)</i> |
| 16.35 | Liver failure in Wilson disease in India | <i>Seema Alam (New Delhi)</i> |
| 16.55 | The importance of mitochondria in rescuing copper induced liver failure | <i>Hans Zischka (Munich)</i> |
| 17.15 | End of day + "family" photo | |
| 18.45 | Walk to restaurant | |
| 19.00 | Dinner at Martin IB, TRÆ, Kalkværksvej 5, Sydhavnen, DK-8000 Aarhus C | |

Saturday May 2
Morning

Session VI: Basic science

Chairs: Hans Zischka, Roman Polishchuk

9.00	Functional Screen of Wilson Variants	<i>Svetlana Lutsenko (Baltimore)</i>
9.20	Trace Copper causes severe Iron Toxicity targeting mitochondrial Iron-Sulfur cluster enzymes	<i>Judith Sailer (Munich)</i>
9.35	Abs: 26 ATP7B close-up: molecular mechanisms of Wilson disease variants	<i>Orsolya Mozner (Aarhus)</i>
9.50	Prion protein promotes copper toxicity in Wilson disease	<i>Roman Polishchuk (Pozzuoli)</i>
10.10	Abs 68: Hidden splicing effects of ATP7B coding Variants revealed by in vivo long-read RNA analysis	<i>Lenka Steiner Mrázová (Prague)</i>
10.25	Coffee break	

Session VII: Screening for WD and disorders of copper metabolism

Chairs: Aftab Ala, Anil Dhawan

11.00	Abs 83: Prospective Longitudinal Characterization of a Cohort of Infantile Wilson Disease	<i>Rima Fawaz (New Haven)</i>
11.15	Current screening programs using ATP7B peptides	<i>Sihoun Hahn (Seattle)</i>
11.30	The parents' perspective	<i>Rhonda Rowland (New York)</i>
11.50	DNA-based newborn screening for disorders of copper metabolism	<i>Stephen Kaler (New York)</i>
12.05	Debate: The baby has a positive test, now what?	<i>Piotr Socha (Warsaw) /Rima Fawaz (New Haven)</i>
12.35	Lunch	

Saturday May 2

Afternoon

Session VIII: Bioavailable copper measurements and liver biochemistries - use for monitoring and diagnosis
Chairs: Aurélie Poujois, Anna Czlonkowska

13.30	ANCC and CuExc	<i>Chris Harrington (Guildford)</i>
13.50	Characterization of Labile Bound Copper by a Dual Filtration Method	<i>Joshua Bornhorst (Rochester)</i>
14.10	Exchangeable copper and REC in 2026	<i>Nouzha Djebrani-Oussedik (Paris)</i>
14.30	TTM: Lost battle or a rising Phoenix?	<i>Fred Askari (Ann Arbor)</i>
14.45	Abs 79: Range of speciated non-ceruloplasmin bound copper over 12-months	<i>Michael Schilsky (New Haven)</i>
15.00	Coffee break	

Session IX: The diagnosis
Chairs: Peter Ott, Michael Schilsky

15.30	Introduction	<i>Peter Ott (Aarhus)</i>
15.40	The value of genetic analysis	<i>Luis García Villarreal (Gran Canaria)</i>
16.00	Wilson Disease – a single gene disorder?	<i>Dorte Lildballe (Aarhus)</i>
16.15	The biopsy, total copper and metallothioneines	<i>Zoe Mariño (Barcelona)</i>
16.35	Leipzig after 2 decades of service	<i>Karl Heinz Weiss (Heidelberg)</i>
16.55	Panel discussion	
17.25	End of day	
18.20	Walk to restaurant	
19.00	Dinner at Havnær, Dagmar Petersens Gade 119, DK-8000 Aarhus C	

Sunday May 3

Morning

Session X: Pharmacotherapeutic advances for WD
Chairs: Zoe Mariño, Piotr Socha

9.00	Unmet needs in the pharmacological treatment of Wilson disease	<i>Aftab Ala (London)</i>
9.15	TDMQ20, a potential new drug for WD	<i>Bernard Meunier (Toulouse)</i>
9.30	Liver biochemistry as surrogate marker in WD	<i>Marina Berenguer (Valencia)</i>
9.45	Abs 30: The Up-Titration Phase of the UNITED Study	<i>Karl Heinz Weiss (Heidelberg)</i>
10.00	Lessons from ⁶⁴ Cu PET	<i>Thomas Sandahl (Aarhus)</i>
10.15	Abs: 85: Methanobactin (ARBM101) facilitates direct hepatic copper capture in pigs	<i>Julie Nagel (Aarhus)</i>
10.30	Coffee break	

Session XI: Curing WD - gene therapy and ATP7B gene repair
Chairs: Eduardo Couchonnal, Tom Warner

11.00	Interim results of the ongoing Ultragenyx Phase 1-3 clinical trial of AAV9 gene therapy for Wilson Disease	<i>Andrew Grimm (Ultragenyx)</i>
11.20	Does liver fibrosis affect AAV treatment?	<i>Pasquale Piccolo (Pozzuoli)</i>
11.40	Genetic modification of ATP7B gene in human cells using RNA-based CRISPR/Cas9 technology	<i>Vanessa Sandfort (Münster)</i>
12.00	Prime editing and gene repair in WD	<i>Tiernan O'Malley (Prime Medicine)</i>
12.20	Abs 55: Modulation of TRPML1/TFEB pathway for the treatment of Wilson Disease	<i>Maria Battipaglia (Pozzuoli)</i>
12.35	Conference summary and take home messages	<i>Michael Schilsky (New Haven)</i>
12.50	Closing remarks	<i>Thomas Sandahl (Aarhus)</i>
12.55	Lunch	
13.50	Departure	





